Immunotherapy in pancreatic adenocarcinoma - Overcoming barriers to response

Ari Rosenberg, Devalingam Mahalingam*

*Corresponding author for this work

Research output: Contribution to journalReview article

17 Scopus citations

Abstract

Pancreatic adenocarcinoma (PAC) remains one of the leading causes of cancer-related death. Despite multiple advances in targeted and immune therapies, the 5-year survival in advanced PAC remains poor. In this review, we discuss some of the unique aspects of the tumor microenvironment (TME) in PAC that may contribute to its resistance to immune therapies, as well as opportunities to potentially overcome some of these inherent barriers. Furthermore, we discuss strategies to enable immune therapies in PAC such as cytotoxic chemotherapy and radiation therapy, cancer vaccines, cytokine based therapy, oncolytic viruses, and adoptive T-cell therapy. Finally, we address a variety of targeted therapies as a strategy to further amplify immune responses in PAC.

Original languageEnglish (US)
Pages (from-to)143-159
Number of pages17
JournalJournal of Gastrointestinal Oncology
Volume9
Issue number1
DOIs
StatePublished - Feb 1 2018

Keywords

  • Immunotherapy
  • Pancreatic cancer
  • Targeted therapies
  • Tumor microenvironment (TME)

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Immunotherapy in pancreatic adenocarcinoma - Overcoming barriers to response'. Together they form a unique fingerprint.

  • Cite this